2602 Pazopanib (Pz) as first line for metastatic renal carcinoma (mRC): Updated validation of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model (IMRCC). The SPAZO study (SOGUG)Begoña Pérez-Valderrama,J. Arranz Arija,M.J. Méndez Vidal,I. García Carbonero,C. Suarez Rodriguez, P. Jiménez Gallego,Marta López-Brea, R.D. García Marrero,J.A. Meana García,Pablo Gajate,Carmen Santander, C. Molins Palau, E.M. Fernandez Parra,O. Reig Torras,Laura Basterrechea,S. Vázquez Estévez, P. Borrega,A. Rodríguez Sánchez,Ángel González Pinto,Daniel CastellanoEUROPEAN JOURNAL OF CANCER（2015）引用 0|浏览8暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
